ARTICLE | Finance

Bear out of Hibernation

Euthymics Bioscience gets $24M from VCs to revive CNS assets from Dov PharmaFrench plays Cerenis, Trophos and Novagali boost VC fortunes

July 26, 2010 7:00 AM UTC

Dov Pharmaceutical Inc. has been slowing dying for a long time, but its neglected assets are now back in play in newco Euthymics Bioscience Inc., which VCs financed with $24 million in a tranched series A round last week.

At the same time, Euthymics completed its merger into Dov, which was announced in February, but taking it private instead of keeping the public listing...